Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Fetal Exposure During Pregnancy Clear all

Conditions: Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Efgartigimod; Biological
Lead sponsor: argenx; Industry
Eligibility: Female only
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Fetal Alcohol Spectrum Disorders
Interventions: No intervention; Other
Lead sponsor: Indiana University; Other
Eligibility: 1 Month to 110 Years
Enrollment: 751 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pregnancy Related
Interventions: Elafibranor; Drug
Lead sponsor: Ipsen; Industry
Eligibility: Female only
Enrollment: 3 participants
Timeline: 2026 – 2039
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Neonatal Abstinence Syndrome
Interventions: Clonidine, Morphine; Drug
Lead sponsor: Henrietta Bada; Other
Eligibility: 12 Hours to 7 Days
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Child Development, Cannabis Use
Interventions: Placebo, Choline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: Female only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Hypoparathyroidism
Interventions: Palopegteriparatide; Drug
Lead sponsor: Ascendis Pharma A/S; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse, Pregnancy
Interventions: Epidiolex; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Chronic Idiopathic Constipation (CIC)
Interventions: No Intervention; Other
Lead sponsor: Takeda; Industry
Eligibility: Female only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chagas Disease
Interventions: Nifurtimox (BAYA2502); Drug
Lead sponsor: Bayer; Industry
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Multiple Locations, West Virginia

Conditions: Postpartum Depression, Posttraumatic Stress Disorder, Infant Behavior, Violence, Parenting
Interventions: Pregnant Moms' Empowerment Program, Nondirective Support Group; Behavioral
Lead sponsor: University of Notre Dame; Other
Eligibility: 3 Months to 55 Years · Female only
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Notre Dame, Indiana • Memphis, Tennessee

Conditions: Cannabis Use Disorder, PREG1, Drug Use, Fetal Exposure During Pregnancy, Neurodevelopmental Abnormality
Interventions: no intervention, this is a purely observational study; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Female only
Enrollment: 168 participants
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Foetal Exposure During Pregnancy
Interventions: Electronic SBI; Behavioral
Lead sponsor: Public Health Institute, California; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Oakland, California • Santa Rosa, California

Conditions: Constipation, Pregnancy
Interventions: No Intervention; Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pregnancy Related
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: Female only
Enrollment: 20 participants
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Environmental Exposure, Pregnancy Related, Preterm Birth, Chronic Respiratory Disease, Neurodegenerative Diseases
Interventions: Educational Intervention; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Galveston, Texas

Conditions: PTSD
Interventions: Written Exposure Therapy (WET), Emotion Focused Supportive Therapy (EFST); Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insomnia Disorder
Interventions: Daridorexant, Non-orexin receptor antagonist insomnia medication, No insomnia medication; Drug · Other
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 2,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Prenatal Exposure Delayed Effects, Multiple Sclerosis, Pregnancy
Interventions: BG9418 (interferon beta-1a); Drug
Lead sponsor: Biogen; Industry
Eligibility: Female only
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Pregnancy, Hyperlipidemias
Interventions: Bempedoic Acid, Bempedoic Acid / Ezetimibe; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Phenylketonuria, Maternal
Interventions: Pegvaliase; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: Female only
Enrollment: 50 participants
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Pregnancy Related, Atopic Dermatitis
Interventions: Ruxolitinib Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 958 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: Morrisville, North Carolina

Search by objective public record fields.

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

Dissecting the Genetics of Fetal Alcohol Spectrum Disorders

Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy

Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain

Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development

A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies

Pregnancy Exposure Registry for Tysabri®

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

Post-Marketing Study of Prucalopride Safety In Pregnancy

An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

Intervention for IPV-exposed Pregnant Women

The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity

Computerized Tool for Preventing Prenatal Drinking

A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy

Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation

Prenatal Education on Environmental Exposures During Pregnancy Study (PEEPS)

Treatment for Antepartum Posttraumatic Stress Disorder/PTSD Study

Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Bempedoic Acid Pregnancy Surveillance Program

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population